Search

Xencor Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

23.38 -0.09

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.11

Max

24.19

Pagrindiniai rodikliai

By Trading Economics

Pajamos

107M

-22M

Pardavimai

47M

51M

Pelnas, tenkantis vienai akcijai

-0.29

Pelno marža

-42.422

Darbuotojai

260

EBITDA

109M

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+36.05% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

423M

1.9B

Ankstesnė atidarymo kaina

23.47

Ankstesnė uždarymo kaina

23.38

Xencor Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-13 20:01; UTC

Xencor Inc shares fell sharply, diverging from recent higher daily closes, amid unusually high trading volume today.

2026-10-09 20:06; UTC

Correlated Moves

Xencor Inc shares are higher, reflecting broader market gains, as the SPDR S&P Biotech ETF rises on news of Moderna's cancer vaccine partnership.

2026-10-08 20:07; UTC

Xencor Inc shares are modestly higher as the broader market recovers from an earlier low, showing a cumulative return of nearly 0.93%.

2026-10-06 20:02; UTC

Correlated Moves

Xencor Inc shares fell sharply, influenced by the declining SPDR S&P Biotech ETF amid concerns over inflation risks and dilution from public offerings.

2026-10-02 19:55; UTC

Xencor Inc shares fell, continuing a four-session decline, after peaking early in the day amid broader weakness in the biotechnology sector.

2026-09-30 20:07; UTC

News

Shares of Xencor Inc. fell sharply despite Wells Fargo initiating coverage with an Overweight rating and a $55.00 price target.

2026-09-29 19:46; UTC

Xencor Inc shares fell sharply, showing unusual volatility and dipping nearly 4% since Monday's close before recovering slightly.

2026-09-28 20:02; UTC

News

Truist Securities raised its price target on Xencor Inc to $29.00, as the stock experiences unusually high volume and continues to gain sharply.

2026-09-24 19:46; UTC

Xencor Inc shares fell sharply, continuing a downward trend since Wednesday and remaining significantly below its 20-day moving average amid broader market weakness.

2026-09-23 20:07; UTC

Correlated Moves

Xencor Inc shares fell sharply, reflecting a broader decline linked to significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

2026-09-22 19:45; UTC

Xencor Inc is modestly higher, continuing positive momentum after four consecutive sessions of gains, despite remaining below its 20-day moving average.

2026-09-21 20:31; UTC

Xencor Inc. has risen in after-market trading, recovering from an initial dip and reaching a peak notably higher than Monday's close.

2026-09-17 20:07; UTC

Correlated Moves

Xencor Inc is advancing, likely supported by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

2026-09-16 19:16; UTC

Xencor Inc is trading roughly flat, having fluctuated within a typical range but remains significantly below its 20-day moving average.

2026-09-15 23:16; UTC

Shares of Xencor Inc. are lower in after-market hours amid broader market pressures and rising yields on the ten-year Treasury note.

2026-09-10 20:07; UTC

Xencor Inc's shares are lower today, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

2026-09-08 20:07; UTC

Xencor Inc shares are trading lower today, following a notable early decline and remaining below their 20-day moving average. No specific news was identified.

2026-09-04 20:07; UTC

Xencor Inc shares are higher, recovering from earlier losses amid broader market selling pressure following a strong jobs report. No specific news was identified.

2026-09-03 22:15; UTC

News

Shares lower in after-market trading after JP Morgan's rating.

2026-09-02 20:08; UTC

Xencor Inc shares are lower today, reversing from an early gain amid a weaker-than-expected ADP employment report affecting investor sentiment on interest rates.

2026-09-01 23:01; UTC

Xencor Inc shares are lower in after-market hours, with no specific news identified. This decline occurs amid broader market concerns over economic growth data.

2026-08-31 20:03; UTC

Xencor Inc shares are higher today, supported by strong trading volume. The stock is above its 20-day moving average and near its one-month range high.

2026-08-28 20:02; UTC

Xencor Inc shares are lower today, breaking a trend of higher closes. The decline occurs amid rising U.S. Treasury yields and high trading volume.

2026-08-27 20:07; UTC

Xencor Inc shares are higher today, recovering from an early dip. The stock is trading well above its 20-day moving average.

2026-08-26 23:01; UTC

Xencor Inc shares are lower in after-market trading amid overall market declines. No specific news was identified to explain the stock's movement.

2026-08-25 19:36; UTC

Xencor Inc shares are higher, supported by declining crude oil prices and lower Treasury yields. The stock remains above its 20-day moving average.

2026-08-24 19:46; UTC

Xencor Inc's shares are higher Monday, rebounding from an earlier low amid rising oil prices and geopolitical tensions, despite no specific company news.

2026-08-21 21:41; UTC

Xencor Inc shares are higher in after-market trading, following a recent trend that shows a 44% increase over the past month.

2026-08-20 19:56; UTC

Correlated Moves

Xencor Inc shares declined during Thursday's session amid broader sector weakness, influenced by negative sentiment following Walmart's disappointing earnings report.

2026-08-19 20:03; UTC

Xencor Inc shares are higher during Wednesday's session, driven by strong market performance and high trading volume. No specific news was identified to explain the move.

Akcijų palyginimas

Kainos pokytis

Xencor Inc Prognozė

Kainos tikslas

By TipRanks

36.05% į viršų

12 mėnesių prognozė

Vidutinis 32 USD  36.05%

Aukščiausias 46 USD

Žemiausias 20 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xencor Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

11

Pirkti

2

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat